COMPASS Pathways

Compass Pathways Plc functions as an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

COMPASS Pathways reports Q4 earnings, faces challenges, explores opportunities

COMPASS Pathways showcased progress in its clinical programs, financial performance, and strategic initiatives. Despite challenges in trial protocols and financial losses, the company remains focused on advancing its treatment options and exploring growth opportunities.

COMPASS Pathways advances Phase 3 TRD program amidst financial challenges

COMPASS Pathways is making progress in their Phase 3 TRD program and maintaining a strong financial position for future developments.
Acceptance of new CPT codes and engagement with health systems present growth opportunities for the company.
However, challenges like financial losses, mixed views on commercialization, and operational differences exist.
Overall, COMPASS Pathways is strategically positioned to capitalize on the evolving landscape of psychedelic therapies.

COMPASS Pathways progresses in trials amidst market challenges and opportunities

COMPASS Pathways is advancing well in trials for treatment-resistant depression and strengthening its market position through IP protection and regulatory milestones.
Challenges lie in differentiation from competitors and establishing unique value propositions, but opportunities exist in FDA support, market growth, and funding flexibility.
Overall, the company's performance, financial stability, and strategic moves position it favorably in the evolving landscape of psychedelic therapies.

COMPASS Pathways reports strong Q3 earnings, eyes transformative 2024

COMPASS Pathways demonstrated robust financial performance in Q3 2023, with strong cash reserves and a strategic private placement financing, positioning the company well for upcoming milestones.
While facing challenges in patient recruitment and trial complexities, COMPASS is leveraging AI models and expanding clinical sites to optimize operations and drive therapeutic innovation.
With Phase III data on the horizon and ongoing advancements in research and development, COMPASS Pathways is poised for a transformative year in 2024, capitalizing on growth opportunities and research insights.

COMPASS Pathways advances COMP360 trials amid financial challenges

COMPASS Pathways' financials show investment in research and development despite net losses, with a strong cash position.
Progress in key trials for COMP360 in TRD and positive safety data indicate promising developments in mental health treatment.
Challenges in enrollment, delays in data, and regulatory monitoring require strategic navigation for future success.
Opportunities lie in collaborations, potential indications, and a focused approach to TRD treatment with COMP360.

COMPASS Pathways advances in clinical trials and strategic partnerships

COMPASS Pathways showcased strong clinical and financial performance in Q1 2024 earnings call, emphasizing progress in Phase III trials and positive PTSD study results
While facing challenges in risk mitigation and therapy comparisons, the company's strategic collaborations and upcoming data releases offer promising opportunities for growth

Compass Pathways faces trial delays, strengthens leadership for commercial success

Compass Pathways navigates delays in pivotal trials while focusing on data disclosure and commercial readiness. New leadership strengthens strategic direction and commercial landscape. Challenges include trial complexities and managing attrition rates, with opportunities in leveraging Phase III data and commercial collaborations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

COMPASS Pathways plc (NASDAQ:CMPS ) Q1 2024 Results Conference Call May 8, 2024 8:00 AM ET Company Participants Stephen Schultz - SVP, IR Kabir Nath - CEO Guy Goodwin - Chief Medical Officer Teri Loxam - CFO Conference Call Participants Vikram Purohit - Morgan Stanley Ritu Baral - TD Cowen Charles Duncan - Cantor Patrick Trucchio - H.C. Wainwright & Co. Tom Shrader - BTIG Sumant Kulkarni - Canaccord Genuity Elemer Piros - Rodman Operator Thank you for standing by, and welcome to the COMPASS Pathways' First Quarter 2024 Earning Investor Call [Operator instructions].

COMPASS Pathways plc (CMPS) Q1 2024 Earnings Call Transcript

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2024 and provided an update on recent business progress.

Compass Pathways Announces First Quarter 2024 Financial Results and Business Highlights

LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today announced top-line results from an open-label phase 2 study evaluating the safety and tolerability of investigational COMP360 psilocybin treatment in 22 patients with post-traumatic stress disorder (PTSD). The study met its primary safety endpoint and available secondary efficacy endpoints. Study observations included meaningful and sustained symptom improvement from baseline in mean CAPS-5 total score, a measure of disease severity, and in Sheehan Disability Scale (SDS) score, a measure of functional impairment in daily life. Administration of COMP360 was well-tolerated, with a safety profile consistent with previous studies.

Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

LONDON, May 03, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the first quarter 2024 ending March 31, 2024, and provide an update on recent business developments, on May 8, 2024.

Compass Pathways to announce first quarter financial results on May 8, 2024

LONDON, May 02, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Mindful Health Solutions (MHS), one of the US's leading providers of innovative behavioral health care, today announced that they have entered into a research collaboration agreement to inform the development of a scalable and cost-effective delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (TRD). This is the latest of several collaborations for Compass, intended to better understand a range of potential approaches to deliver COMP360 to patients in different care settings.

Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

LONDON, April 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Journey Clinical, a leading psychedelic-assisted psychotherapy platform with the largest network of licensed therapists focused on psychedelics in the US, today announced they have entered into a research collaboration agreement to inform the development of a scalable and practical delivery and healthcare provider training model for COMP360 psilocybin treatment, if approved for treatment-resistant depression (TRD).

Compass Pathways and Journey Clinical establish research collaboration agreement to inform the training of healthcare providers and delivery model for COMP360 psilocybin treatment, if approved for treatment-resistant depression

LONDON, April 01, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will present at the 23rd Annual Needham Virtual Healthcare Conference at 8:00am ET on April 9, 2024.

Compass Pathways to participate in upcoming 23rd Annual Needham Virtual Healthcare Conference

David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair David Norton Assumes Role of Interim Board Chair while the Company Runs a Global Search for a New Chair

Compass Pathways Board Chair and Co-Founder George Goldsmith and Co-Founder Ekaterina Malievskaia Step Down from Board of Directors

Catalyst Pharmaceuticals

Vertex Pharmaceuticals

Vertex Pharmaceuticals is angling to treat acute pain with its new drug. Compass Pathways will have a major data update sometime in Q4.

3 Biopharma Stocks You Don't Want to Miss in the New Bull Market

COMPASS Pathways plc (CMPS) Q4 2023 Earnings Call Transcript

LONDON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the fourth quarter 2023 and provided an update on recent progress across its business.

Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights

Euroseas

Uranium Energy

There are some great microcap stocks for investors to scoop up this month. The broader indices, such as the S&P 500 and the Nasdaq, are showing signs of both strength and weakness, but I believe that there's still a lot of gas left in the tank for these to surge higher.

Penny Power Players: 3 Stocks to Watch in the Microcap Arena

LONDON, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference at 12:50 pm ET on March 4, 2024.

Compass Pathways to participate in upcoming TD Cowen investor conference

LONDON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and year-end 2023 ending December 31, 2023, and provide an update on recent business developments, on February 29, 2024.

Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024

Acadia Healthcare

Bristol-Myers

The New York Times published an article in early February about mental health and the failure of New York City to carefully audit its program to treat mentally ill people living on the streets. When I read articles like this, it makes me think about possible related investments.

Mental Health Mavericks: 3 Stocks Changing the Game

Compass will report some critical clinical trial data this year. One of its peers could soon see its first drug approved.

Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.

Compass Pathways plc, a biotech company based in London, is developing a psilocybin-based therapy for CNS disorders. The company's shares declined by over 80% in 2022 due to safety concerns and regulatory hurdles.

Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play

LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Oppenheimer 34th Annual Healthcare Life Sciences Conference at 2:00 pm ET on February 13, 2024.

Compass Pathways to participate in upcoming Oppenheimer investor conference

LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, and Hackensack Meridian Health (“HMH”), a leading not-for-profit health care organization and the largest, most comprehensive and truly integrated network in New Jersey, today announced that that they have entered into a research collaboration agreement to inform the delivery model design of investigational COMP360 psilocybin treatment, if FDA-approved.

Compass Pathways enters into research collaboration agreement with Hackensack Meridian Health to develop optimal clinical model for investigational COMP360 psilocybin treatment, if FDA-approved

Atai Life Sciences BV

Seelos Therapeutics

Though psychedelic therapies and related psychedelic stocks have fallen out of favor recently, there's still tremendous research and insight happening beneath the surface. Even Elon Musk uses ketamine as a depression therapeutic.

Therapy's New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution

Mind Medicine MindMed

Critical catalysts are approaching in the psychedelic sector, with the potential for the first FDA-approved psychedelic therapy by the end of the year.

De-Risking Psychedelics: Compass Pathways, Cybin And Atai

Psychedelics stocks could be buoyed by a few positive events soon. The government is now funding the study of certain psychedelics.

3 Big New Catalysts for Psychedelics Stocks in 2024

Johnson & Johnson

A financial backer of an effort to legalize the drug MDMA for therapeutic use sees the potential for “exponential growth” should it win approval from the U.S. Food and Drug Administration, possibly over this summer.

Why one backer of MDMA therapy sees ‘exponential' growth following FDA approval this year

Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions Initial safety findings at 24 hours post dosing were consistent with studies of COMP360 in other psychiatric conditions

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

LONDON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced that it has appointed Teri Loxam as Chief Financial Officer (CFO), effective the beginning of March 2024. She will be based in the company's New York City office. Teri will serve as an advisor during the period leading up to her appointment as CFO.

News for COMPASS Pathways Stock (CMPS)